stockrowAmylyx Pharmaceuticals, Inc. (AMLX) vs Indivior Pharmaceuticals Inc. (SUPN)
- Amylyx Pharmaceuticals, Inc. AMLX 29.01 +5.03%
- Indivior Pharmaceuticals Inc. SUPN 26.49 −0.93%
Amylyx Pharmaceuticals, Inc. and Indivior Pharmaceuticals Inc. are both Drug Manufacturers Specialty & Generic companies. Indivior Pharmaceuticals Inc. is the larger, with a market value of $5.6B against $3.5B — 1.6× the size. Amylyx Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; Indivior Pharmaceuticals Inc. trades at 7.6×. Indivior Pharmaceuticals Inc. grew revenue faster over the last twelve months: 16.4% against −77.1%. Indivior Pharmaceuticals Inc. has the higher net margin (32.9% vs 0.00%) and the higher return on invested capital (283.0% vs 0.00%). Across the 16 metrics below, Indivior Pharmaceuticals Inc. leads on 14 and Amylyx Pharmaceuticals, Inc. on 2.
Valuation
Profitability
| Metric | AMLX | SUPN | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | (42.65%) | 84.85% | 53.51% |
| Operating margin | 0.00% | 40.57% | 0.00% |
| Net margin | 0.00% | 32.85% | (2.45%) |
| Free cash flow margin | 0.00% | 2.26% | 0.00% |
| Return on equity | (74.73%) | (337.83%) | (0.80%) |
| Return on assets | (66.25%) | 32.82% | (1.67%) |
| Return on invested capital | 0.00% | 283.03% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack